Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Christopher R. Grant; Elaine J. Chiao; Zhaohui L. Arter; Cary Johnson; Truc Tran; Farshid Dayyani; Krishnasu Tewari; Valery Vilchez; Joseph Carmichael; May Cho

doi:10.12659/AJCR.939448

29 June 2023: Articles

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology

Christopher R. Grant ^A* , Elaine J. Chiao ^E , Zhaohui L. Arter ^A , Cary Johnson ^C , Truc Tran ^B , Farshid Dayyani ^E , Krishnansu Tewari ^E , Valery Vilchez ^E , Joeseph Carmichael ^E , May Cho ^A

DOI: 10.12659/AJCR.939448

Am J Case Rep 2023; 24:e939448

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 4. Timeline of case report.

Back to the Article

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review

Your Privacy